Zoetis Reports Modest Revenue Growth in Q1 2025

Zoetis ( (ZTS) ) has released its Q1 earnings. Here is a breakdown of the information Zoetis presented to its investors.

Zoetis Inc., a leading animal health company, specializes in developing and manufacturing vaccines, medicines, and diagnostic products for pets and livestock across over 100 countries. In its first quarter of 2025, Zoetis reported a revenue of $2.2 billion, marking a 1% increase from the previous year, and a net income of $631 million, reflecting a 5% rise. The company achieved a 9% organic operational growth in revenue, driven by strong demand for its innovative products, particularly in the companion animal segment. Zoetis’ U.S. revenue grew by 2%, with companion animal product sales increasing by 8%, while international revenue remained flat on a reported basis but grew 11% operationally. The company updated its full-year 2025 revenue guidance to between $9.425 billion and $9.575 billion, adjusting for foreign exchange impacts and maintaining its organic operational growth outlook of 6% to 8%. As Zoetis continues to navigate an evolving external environment, it remains focused on innovation and customer support, with a commitment to delivering shareholder value.